2025-12-19 - Analysis Report
Okay, here's a comprehensive analysis of Natera (NTRA) based on the provided data, broken down into the requested sections.

**0) Report Structure:**

The report will first present the raw data (numbers) as requested.  Then, simple analysis/interpretation of those numbers will follow each section. Finally, a summary.

**1) Return Rate Comparison:**

*   **Ticker:** NTRA (Natera Inc)
*   **Company Overview:** Natera is a diagnostics company specializing in cell-free DNA testing.
*   **NTRA Cumulative Return:** 130.27%
*   **VOO (S&P 500) Cumulative Return:** 99.35%
*   **Divergence:** 36.2 (Range: Min -88.5, Max 174.8, Relative Divergence: 47.4)

**Analysis:**

*   NTRA has significantly outperformed the S&P 500 (VOO) over the tracked period, with a 130.27% cumulative return versus VOO's 99.35%.
*   The divergence of 36.2 indicates that NTRA's outperformance, while substantial, is roughly in the middle of its historical divergence range with the S&P 500.  The 47.4 relative divergence suggests it's closer to the lower end of its outperformance spectrum compared to its historical extremes.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD   | Alpha    | Beta  | Cap(B) |
| :---------- | :------- | :------ | :------- | :---- | :----- |
| 2015-2017  | -10.0%   | 70.1%  | -34.0%   | -0.2  | 1.2    |
| 2016-2018  | 22.0%    | 80.0%  | 6.0%     | 0.1   | 1.9    |
| 2017-2019  | 50.0%    | 80.0%  | 28.0%    | 1.0   | 4.7    |
| 2018-2020  | 186.0%   | 80.5%  | 163.0%   | 1.1   | 13.9   |
| 2019-2021  | 96.0%    | 80.5%  | 49.0%    | 1.6   | 13.0   |
| 2020-2022  | -77.0%   | 80.5%  | -76.0%   | 0.1   | 5.6    |
| 2021-2023  | -194.0%  | 76.6%  | -195.0%  | -1.1  | 8.7    |
| 2022-2024  | 8.0%     | 76.6%  | -13.0%   | -1.2  | 22.1   |
| 2023-2025  | 157.0%   | 76.6%  | 94.0%    | 0.1   | 31.3   |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  NTRA's CAGR has been highly volatile, ranging from -194% to +186% over different 3-year periods. This highlights the stock's high-growth, high-risk nature.
*   **MDD (Maximum Drawdown):**  The MDD figures consistently show significant downside risk, typically around 70-80%. This confirms the potential for substantial losses.
*   **Alpha:** Alpha measures the investment's performance relative to the market.  NTRA's Alpha is also highly variable.  Periods of strong outperformance (positive Alpha) are interspersed with periods of significant underperformance (negative Alpha).
*   **Beta:** Beta measures the stock's volatility relative to the market. The Beta values fluctuate and are close to 1, it means that the stock's price tends to move in the same direction as the market.
*   **Cap(B):** Market Capitalization in Billions. Shows the company growth.

**2) Recent Stock Price Fluctuations:**

*   **Close:** 224.74
*   **Last-Market:** Price: 224.74, Previous Close: 225.49, Change: -0.33
*   **5-day SMA:** 227.596
*   **20-day SMA:** 234.1795
*   **60-day SMA:** 202.3618

**Analysis:**

*   The stock is currently trading below both its 5-day and 20-day simple moving averages (SMAs), suggesting a short-term downward trend.
*   The 60-day SMA is well below the 5 and 20 day SMA which indicates that the stock has been generally trending upward over the last 2 months, but in the short-term the prices went down.

**3) RSI, PPO, Divergence Change, Expected Return:**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment Recommended)
*   **RSI:** 27.42 (Oversold)
*   **PPO:** -1.48
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (4 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -2.4 (Negative – Indicates Short-Term Decline)
*   **Expected Return (%):** -50.6% (Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point)

**Analysis:**

*   **MRI:**  A score of 0.7 suggests a medium level of investment risk, indicating that the stock might be suitable for investors with a moderate risk tolerance.
*   **RSI:**  The RSI of 27.42 indicates that the stock is currently oversold, which *could* suggest a potential buying opportunity. However, oversold conditions can persist for extended periods.
*   **PPO:** The negative PPO indicates that the shorter-term moving average is below the longer-term moving average, confirming the short-term downward trend.
*   **Hybrid Signal:** The signal suggests a full investment strategy, implying that the current valuation and risk profile are favorable.
*   **Divergence Change:** The negative change in relative divergence over the past 20 days confirms recent underperformance relative to the S&P 500.
*   **Expected Return:** The large negative expected return is a concerning signal. It suggests that, based on current analysis, an investment in NTRA is projected to underperform the S&P 500 significantly over the long term. This is likely heavily influenced by the recent price decline.

**4) Recent News & Significant Events:**

*   **[2025-11-24] This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He’s Buying Now. - Yahoo Finance** (Implies potential positive sentiment, depending on whether NTRA is mentioned).
*   **[2025-12-18] Blood test helps spot colon cancer patients who gain from celecoxib - Stock Titan** (Potentially positive, if related to Natera's technology or collaborations).
*   **[2025-12-18] Thrivent Financial for Lutherans Cuts Stake in Natera, Inc. $NTRA - MarketBeat** (Negative, as institutional selling pressure can depress the stock price).
*   **[2025-12-15] Barclays Raises Natera (NTRA) Price Target to $270 | NTRA Stock News - GuruFocus** (Positive, indicates analyst confidence).
*   **[2025-12-18] Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Natera (NTRA) - The Globe and Mail** (Positive, overall positive sentiment).
*   **[2025-11-30] Why Natera Remains A 'Hold' For Me Despite Surging MRD Growth And Fatter Margins - Seeking Alpha** (Neutral, suggests that while the company has positive aspects, it may not be a strong buy at the current valuation).

**Analysis:**

*   The news is mixed. Analyst upgrades (Barclays) and bullish sentiment articles are positive.  However, the institutional selling (Thrivent) is a concern. The Seeking Alpha article suggests a more cautious approach.

**4-2) Analyst Opinions:**

*   **Consensus:** Strong Buy (~1.47)
*   **Opinions:** 19
*   **Target Price (avg/high/low):** 244.42 / 280.00 / 186.00

**Analysis:**

*   Despite the recent price weakness, the analyst consensus remains strongly bullish. The average target price of $244.42 suggests significant upside potential from the current price. However, the range of target prices is wide, indicating differing opinions on the company's valuation.

**5) Recent Earnings Analysis:**

| 날짜       | EPS   | 매출        |
| :---------- | :----- | :---------- |
| 2025-11-07  | -0.64 | 0.59 B$     |
| 2025-08-08  | -0.74 | 0.55 B$     |
| 2025-05-09  | -0.5  | 0.50 B$     |
| 2024-11-12  | -0.26 | 0.44 B$     |
| 2025-11-07  | -0.26 | 0.44 B$     |

**Analysis:**

*   Natera is currently not profitable. While revenue has been growing, the company continues to report losses per share (EPS). The most recent EPS figures indicate continued unprofitability.

**6) Financial Information:**

Revenue and Profitability:

| Quarter      | Revenue  | Profit Margin |
| :------------ | :------- | :------------ |
| 2025-09-30  | $0.59B  | 64.91%        |
| 2025-06-30  | $0.55B  | 63.41%        |
| 2025-03-31  | $0.50B  | 63.12%        |
| 2024-12-31  | $0.48B  | 62.94%        |
| 2024-09-30  | $0.44B  | 61.79%        |

Capital and Profitability:

| Quarter      | Equity   | ROE      |
| :------------ | :-------- | :-------- |
| 2025-09-30  | $1.25B  | -6.99%   |
| 2025-06-30  | $1.25B  | -8.10%   |
| 2025-03-31  | $1.24B  | -5.40%   |
| 2024-12-31  | $1.20B  | -4.50%   |
| 2024-09-30  | $0.88B  | -3.60%   |

**Analysis:**

*   **Revenue:** Revenue is consistently increasing, indicating positive sales growth.
*   **Profit Margin:** The profit margin is high and stable, suggesting that Natera has good control over its cost of goods sold.
*   **Equity:** The total equity is steadily increasing.
*   **ROE (Return on Equity):** The negative ROE reflects the company's current unprofitability.  While improving over time, the negative values indicate that the company is not generating profits from its equity.

**7) Comprehensive Analysis (Summary):**

*   **Overall:** NTRA is a high-growth, high-risk diagnostics company. It has significantly outperformed the S&P 500 in the past, but its performance is highly volatile.
*   **Financials:** Revenue is growing strongly, and profit margins are high. However, the company is currently unprofitable, as demonstrated by negative EPS and ROE.
*   **Technicals:** The stock is currently in a short-term downward trend, as indicated by the moving averages and the negative change in relative divergence. The RSI suggests it is oversold.
*   **Sentiment:** Analyst sentiment is generally bullish, with a strong buy consensus and significant upside potential based on target prices. However, recent news includes an institutional sell-off, which is a negative signal.
*   **Key Concerns:** The primary concern is the company's unprofitability and the recent negative expected return, which suggests potential underperformance relative to the S&P 500.

**Conclusion:**

NTRA presents a mixed picture. While it has strong growth potential and positive analyst sentiment, the current unprofitability and recent price weakness warrant caution. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in NTRA. The mixed news flow and technical indicators suggest potential near-term volatility.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.